

Nucryst Pharmaceuticals

[View the current Nucryst Pharmaceuticals Page on BioPortfolio.com](http://www.bioportfolio.com/biocorporate/27398-Nucryst+Pharmaceuticals.html)

(<http://www.bioportfolio.com/biocorporate/27398-Nucryst+Pharmaceuticals.html>)

Contact Details:

50 Audubon Road, Suite B
Wakefield
Massachusetts
01880
United States of America

Tel: (781) 224-1444

Fax: (781) 246-6002

Email: info@nucryst.com

Companies are created from a vision, by thinking strategically and passionately to turn a sound idea into reality. NUCRYST Pharmaceuticals Corp's start came from the desire to improve and broaden silver's therapeutic properties. Using their understanding of quantum mechanics, NUCRYST scientists started thinking small: nano small approaching the quantum/atomic scale. Small variations in structure and composition of nanoscale materials can have a dramatic effect on physical, chemical, biological properties of materials. In 1991, NUCRYST developed a process of forming a thin film of silver nanocrystals to base materials utilizing a custom synthesis called reactive magnetron sputtering, which is a type of physical vapor deposition. The silver nanocrystals are formed atom by atom in a disordered fashion. Since this early discovery of its proprietary silver nanocrystalline coating, NUCRYST went on to manufacture, receive regulatory clearance for, and launch the first product, Acticoat™ with SILCRYST™ nanocrystals antimicrobial barrier burn dressings in 1998, with its own sales force. In 2001, NUCRYST entered into its first licensing agreement with Smith & Nephew for the sale, distribution and marketing of Acticoat™ dressings with SILCRYST™ nanocrystals. NUCRYST's agreement with Smith & Nephew give it the benefits of Smith & Nephew's leading worldwide marketing and distribution network, product development expertise and global regulatory capability. Healthcare professionals around the world use Smith & Nephew's Acticoat™ dressings for use in serious wounds, including life-threatening burns and chronic wounds

Recent Publications by Nucryst Pharmaceuticals:



- [Effects of nanocrystalline silver \(NPI 32101\) in a rat model of ulcerative colitis.](#)
Nanocrystalline silver (NPI 32101) has been demonstrated to have... 27th October, 2007
NUCRYST Pharmaceuticals Inc., 50 Audubon Road, Wakefield, MA 01880, USA.- Dig Dis Sci. 2007 Oct;52(10):2732-42. Epub 2007 Apr 12. ([DOI Direct Link](#))
- [Topical nanocrystalline silver cream suppresses inflammatory cytokines and induces apoptosis of](#)

[inflammatory cells in a murine model of allergic contact dermatitis.](#)

*BACKGROUND: Nanocrystalline silver has both antimicrobial and...*5th August, 2005

NUCRYST Pharmaceuticals Inc., 50 Audubon Road, Wakefield, MA 01880, USA.- Br J Dermatol. 2005 Jun;152(6):1235-42. ([DOI Direct Link](#))

- [Anti-inflammatory effect of topical nanocrystalline silver cream on allergic contact dermatitis in a guinea pig model.](#)

*The anti-inflammatory activity of topical nanocrystalline silver cream was...*9th July, 2004

NUCRYST Pharmaceuticals Inc, Wakefield, Massachusetts 01880, USA.- Clin Exp Dermatol. 2004 May;29(3):282-7. ([DOI Direct Link](#))

Press Releases on Nucryst Pharmaceuticals:

Transcept Pharmaceuticals Scheduled to Meet With FDA to Discuss Intermezzo(R) Complete Response Letter	23rd November, 2009	Transcept Pharmaceuticals, Inc.	<i>POINT RICHMOND, Calif., Nov. 23 /PRNewswire-FirstCall/ -- Transcept Pharmaceuticals, Inc. (Nasdaq: TSPT) today announced that it is scheduled to meet with the U.S. Food and Drug Administration (FDA)</i>
NCCN Updates NHL Guidelines to Incorporate FDA Approvals of New Treatment Options	23rd November, 2009	National Comprehensive Cancer Network	<i>Following the FDA approvals of two new therapies for Non-Hodgkin's Lymphomas (NHL), the NCCN Guidelines for NHL have been updated to include ofatumumab (Azerra(TM), GlaxoSmithKline) as a therapy</i>
Poniard Announces \$7.4 Million Financing	23rd November, 2009	Poniard Pharmaceuticals	<i>SAN FRANCISCO, Nov. 23 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals (Nasdaq: PARD) today announced the sale of 3,465,878 of its common shares to Azimuth Opportunity Ltd. for gross proceeds of</i>
Ligon Discovery Announces Appointment of Errol B. De Souza as Executive Chairman	23rd November, 2009	Ligon Discovery, Inc.	<i>CAMBRIDGE, Mass., Nov. 23 /PRNewswire/ -- Ligon Discovery, Inc., which uses proprietary small molecule microarray technology to find drugs against high-value targets, today announced the appointment</i>

[Caldolor\(R\) \(Ibuprofen\)
Injection Demonstrates
Significant Fever
Reduction in Hospitalized
Burn Patients](#)

23rd November,
2009

Cumberland
Pharmaceuticals Inc.

NASHVILLE, Tenn., Nov. 23
/PRNewswire-FirstCall/ --
Cumberland Pharmaceuticals
Inc. (Nasdaq: CPIX) today
announced positive new top-line
results from a study evaluating
the safety and efficacy of

BioNews Results for Nucryst Pharmaceuticals



- [Smith & Nephew to buy Nucryst Pharmaceuticals technology](#)
Business Journal of Tampa Bay: Nov 15 2009 4:44PM Matching: nucryst pharmaceuticals
- [Westaim announces 2009 third quarter results](#)
KLFY: Nov 14 2009 3:55AM Matching: nucryst pharmaceuticals
- [NUCRYST announces 2009 third quarter financial results](#)
TickerTech.com: Nov 14 2009 10:08PM Matching: nucryst pharmaceuticals
- [NUCRYST announces 2009 third quarter financial results](#)
Montana's News Station: Nov 14 2009 5:59PM Matching: nucryst pharmaceuticals
- [NUCRYST announces 2009 third quarter financial results](#)
KSLA: Nov 14 2009 4:29PM Matching: nucryst pharmaceuticals
- [NUCRYST announces 2009 third quarter financial results](#)
KLFY: Nov 14 2009 3:55AM Matching: nucryst pharmaceuticals
- [Westaim announces 2009 third quarter results](#)
Montana's News Station: Nov 14 2009 5:59PM Matching: nucryst pharmaceuticals
- [Westaim announces 2009 third quarter results](#)
KSLA: Nov 14 2009 4:29PM Matching: nucryst pharmaceuticals
- [Smith & Nephew to buy Nucryst Pharmaceuticals technology](#)
Business Journal of Tampa Bay: Nov 13 2009 7:34AM Matching: nucryst pharmaceuticals
- [Nucryst Pharmaceuticals earns \\$493,000 \(U.S.\) in Q3](#)
Stockwatch: Nov 13 2009 11:40PM Matching: nucryst pharmaceuticals
- [Smith & Nephew to acquire operations and assets of Nucryst Pharma](#)
PharmaBiz: Nov 13 2009 12:12PM Matching: nucryst pharmaceuticals
- [Nucryst Pharma Turns To Profit In Q3 - Quick Facts](#)
RTTNews.com: Nov 13 2009 10:11PM Matching: nucryst pharmaceuticals
- [Nucryst Pharma Turns To Profit In Q3 - Quick Facts](#)
RTTNews.com: Nov 13 2009 10:11PM Matching: nucryst pharmaceuticals
- [Smith & Nephew to acquire Nucryst Pharmaceuticals in Canada - Zib...](#)
Zibb: Nov 12 2009 4:19PM Matching: nucryst pharmaceuticals
- [Healthcare Watch: Nucryst Pharmaceuticals](#)
TradingMarkets: Nov 12 2009 9:27AM Matching: nucryst pharmaceuticals



Nucryst Pharmaceuticals Patents:

- 7470437- [Methods of treating conditions with a metal-containing material](#)
- 6692773- [Treatment of hyperproliferative skin disorders and diseases](#)
- 6719987- [Antimicrobial bioabsorbable materials](#)
- 6723350- [Lubricious coatings for substrates](#)
- 6939568- [Treatment of inflammatory skin conditions](#)
- 6989156- [Therapeutic treatments using the direct application of antimicrobial metal compositions](#)
- 6989157- [Dry powders of metal-containing compounds](#)
- 7008647- [Treatment of acne](#)
- 7078060- [Solutions and aerosols of metal-containing compounds](#)
- 7087249- [Treatment of mucosal membranes](#)
- 7137968- [Transcutaneous medical device dressings and method of use](#)
- 7255881- [Metal-containing materials](#)
- 7427416- [Methods of treating conditions using metal-containing materials](#)
- 6365220- [Process for production of actively sterile surfaces](#)

BioCorporate Profiles - upgrade to a full profile

BioPortfolio's BioCorporate full profiles offers your organization the opportunity to increase internet traffic to your corporate web site and enhance awareness of your business, technology, products and services. BioCorporate profiles are dynamic and are updated weekly with new information sourced from core information resources: publications, clinical trials, patents and global news.

Why you should upgrade your BioPortfolio BioCorporate profile:

- the ability to amend and add information on products and services to your profile using a membership username and password
- the option to add a corporate logo
- the creation of high value URL links back to your organization's website which will improve search engine ranking - resulting in increased site traffic
- the option have your press releases published on BioPortfolio and distributed via our BioNewsCast service
- an enhanced BioCorporate profile will also improve your exposure on BioPortfolio's related service InDepth and GeneDB

The annual cost is \$995.00 for established organizations and \$495.00 for organizations less than 12 months old.

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road, Dorchester, Dorset, DT1 1PW, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2009 - BioPortfolio Limited.

